PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Dr. Joseph Joyce, Director At Merck & Co. to Speak At Vaccines Meeting on November 7-8 in Boston, Massachusetts - Dr. Joseph Joyce, Director, Vaccine Research, Merck Research Laboratories, to deliver featured speech at 9th Annual Vaccines Discovery and Development: All Things Considered Conference (Nov. 7-8, in Boston, MA) - GTCbio.com
Dr. Joseph Joyce, Director At Merck & Co. to Speak At Vaccines Meeting on November 7-8 in Boston, Massachusetts

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/08/16 - Dr. Joseph Joyce, Director, Vaccine Research, Merck Research Laboratories, to deliver featured speech at 9th Annual Vaccines Discovery and Development: All Things Considered Conference (Nov. 7-8, in Boston, MA) - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Dr. Joseph Joyce, Director, Vaccine Research, Merck Research Laboratories, to deliver featured presentation at the “9th Annual Vaccines Discovery and Development: All Things Considered” conference, to be held on Nov. 7-8, 2011 in Boston, MA by GTC.

Dr. Joseph Joyce will discuss M-Protein-derived peptide conjugate vaccine candidates for Streptococcus pyogenes. Group A Streptococcus (GAS) infections caused by S. pyogenes represent a major health care burden in both developed and developing nations. Disease etiology ranges from mild pharyngitis to life-threatening manifestations such as necrotizing fasciitis and toxic shock syndrome. In a percentage of individuals, post-infection sequelae can lead to serious autoimmune manifestations such as rheumatic fever and glomerulonephritis. While first line antibiotics are generally effective, recurrent infection and limited accessibility to therapeutics in the developing world where incidence of severe disease is highest drive the need for prophylactic vaccine development.

Dr. Joseph Joyce joined Merck in 1989, working as a protein biochemist in the area of vaccine research. He holds post graduate degrees in Chemistry (M.S.) and Biochemistry (Ph.D.) from Lehigh University. During his early tenure at Merck, Joyce worked on several important vaccine programs including Recombivax® for hepatitis B, pneumococcal conjugate, and human papillomavirus (HPV). He played a key role in early development of Gardasil®, the first licensed HPV vaccine, establishing purification and characterization protocols for HPV virus-like particles produced in yeast, and studying interaction of these VLPs with mammalian cell surface receptors.

The 9th Vaccine Discovery and Development: All Things Considered conference annually brings together experts in vaccines from big and small pharmaceutical companies, academia, and government. The intimate setting of the conference enables networking and the opportunity to meet speakers and delegates. This year’s conference will appropriately take place in Boston, MA, the hub of research and development.

The purpose of the event is to generate dialogue and to introduce novel advances in the field of vaccines. It is part of a two-track meeting that will take place at the Omni Parker House. Delegates at this event will have a chance to meet the attendees of the concurrent 8th Anti-Infectives Partnering and Deal-Making conference.

The sessions for this conference are:

• Vaccines for Infectious Diseases;
• Therapeutic Vaccines;
• Regulatory and Government Policy;
• New Technologies in Vaccine Development;
• Future Trends in Vaccine Discovery and New Vaccines.

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Dr. Joseph Joyce, Director At Merck & Co. to Speak At Vaccines Meeting on November 7-8 in Boston, Massachusetts

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)